Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 13/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | AKT2 | P31751 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.46 |
| ▸ | JAK1 | P23458 | 3/20 | 0.44 |
| ▸ | TEC | P42680 | 1/20 | 0.44 |
| ▸ | TXK | P42681 | 1/20 | 0.44 |
| ▸ | BLK | P51451 | 1/20 | 0.44 |
| ▸ | BMX | P51813 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.44 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3960604 | 0.76 | JAK3 (1.00) | JAK3LCKAKT2GSK3BKIT | |
| SCHEMBL3956876 | 0.71 | JAK3 (0.89) | JAK3LCKAKT2GSK3BKIT | |
| SCHEMBL2024604 | 0.69 | JAK3 (1.00) | JAK3LCKAKT2GSK3BKIT | |
| SCHEMBL10079358 | 0.69 | JAK3 (1.00) | JAK3LCKAKT2GSK3BKIT | |
| SCHEMBL2021330 | 0.69 | JAK3 (1.00) | JAK3LCKAKT2GSK3BKIT | |
| SCHEMBL2019457 | 0.69 | LCK (1.00) | JAK3LCKAKT2GSK3BKIT | |
| SCHEMBL3952874 | 0.69 | JAK3 (0.75) | JAK3LCKAKT2GSK3BKIT | |
| SCHEMBL2016053 | 0.69 | JAK3 (1.00) | JAK3LCKAKT2GSK3BKIT | |
| SCHEMBL3953429 | 0.68 | JAK3 (0.65) | JAK3LCKAKT2GSK3BKIT | |
| SCHEMBL3954391 | 0.68 | JAK3 (1.00) | JAK3LCKAKT2GSK3BKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3248980-B1 | JAK INHIBITOR | WUXI FORTUNE PHARMACEUTICAL CO LTD (CN) | 2023-09-06 | — | — | EP | disclosed |
| US-10617690-B2 | JAK inhibitor | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2020-04-14 | — | — | US | disclosed |
| US-20170360794-A1 | JAK INHIBITOR | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2017-12-21 | — | — | US | disclosed |
| US-20170360794-A1 | JAK INHIBITOR | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2017-12-21 | — | — | US | disclosed |
| US-20170360794-A1 | JAK INHIBITOR | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2017-12-21 | — | — | US | disclosed |
| EP-3248980-A1 | JAK INHIBITOR | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016116025-A1 | JAK INHIBITOR | 南京明德新药研发股份有限公司 | 2016-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360794-A1 | JAK INHIBITOR | JAK2, JAK1, JAK3 | JAK3 3/4885LCK 15/4885AKT2 540/4885 |
| US-10617690-B2 | JAK inhibitor | JAK2, JAK1, JAK3 | JAK3 3/4885LCK 15/4885AKT2 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.